We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Pre-op surgery

3 February 2021 By Aimee Donnellan

The $89 bln health group is pressing on with a plan to spin off its consumer drugs unit. But its shares are depressed by slow growth and competition in the core pharma division, requiring risky investment and M&A. A dividend chop at least gives CEO Emma Walmsley some elbow room.

This content is for Subscribers only

 

Email a friend

Please complete the form below.

Required fields *

*
*
*

(Separate multiple email addresses with commas)